Check for updates

REVIEW

Nocturia: consequences, classification, and management

[version 1; peer review: 3 approved]Noam D. Fine ¹, Jeffrey P. Weiss¹, Alan J. Wein²¹Department of Urology, SUNY Downstate Medical Center, Brooklyn, New York, USA²Division of Urology, University of Pennsylvania, Philadelphia, Pennsylvania, USA**V1** First published: 01 Sep 2017, 6(F1000 Faculty Rev):1627
<https://doi.org/10.12688/f1000research.11979.1>Latest published: 01 Sep 2017, 6(F1000 Faculty Rev):1627
<https://doi.org/10.12688/f1000research.11979.1>**Abstract**

Nocturia is a widespread condition that can negatively impact quality of sleep and overall health. This condition is multifactorial in nature and is best approached through the analysis of frequency volume charts. Through these charts, clinicians may classify each individual case of nocturia into one of four distinct categories: global polyuria, nocturnal polyuria, reduced bladder capacity, and mixed. Treatments should then be tailored to each individual based upon the category of their nocturia. In some cases, appropriate therapy will consist of behavioral modification techniques or addressing underlying systemic diseases. In other cases, medical therapy may be necessary, but, to date, medications have shown limited efficacy at treating nocturia.

Keywords

Nocturia, urology, overactive bladder

Open Peer Review**Approval Status**

	1	2	3
version 1 01 Sep 2017

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Osamu Yokoyama**, University of Fukui, Fukui, Japan
2. **Altaf Mangera**, Sheffield Teaching Hospitals NHS Trust, Royal Hallamshire Hospital, Sheffield, UK
3. **Jin Wook Kim**, Chung-Ang University, Seoul, South Korea

Any comments on the article can be found at the end of the article.

Corresponding author: Noam D. Fine (noam.fine@downstate.edu)

Author roles: Fine ND: Writing – Original Draft Preparation; Weiss JP: Writing – Review & Editing; Wein AJ: Writing – Review & Editing

Competing interests: Noam D. Fine declares that he has no competing interests. Jeffrey P. Weiss declares that he is an advisor for Ferring, Pfizer, Elsevier, Astellas, Allergan, Vantia, and Symptelligence. Alan J. Wein declares that he is an advisor for Allergan, AltheRx, Astellas, Axonics, Medtronic, and Serenity.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2017 Fine ND *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Fine ND, Weiss JP and Wein AJ. **Nocturia: consequences, classification, and management [version 1; peer review: 3 approved]** F1000Research 2017, 6(F1000 Faculty Rev):1627 <https://doi.org/10.12688/f1000research.11979.1>

First published: 01 Sep 2017, 6(F1000 Faculty Rev):1627 <https://doi.org/10.12688/f1000research.11979.1>

Introduction

Nocturia is a prevalent and highly bothersome lower urinary tract symptom (LUTS). In 2002, the International Continence Society (ICS) defined nocturia as “the complaint that the individual has to wake at night one or more times to void”¹. There has since been much debate around this definition, and it was revised in 2017 to be “waking to pass urine during the main sleep period”². Part of the controversy over the original definition stemmed from the fact that there may be no “complaint” from those who wake only once during the night to void, as a single episode of nocturia may not be bothersome at all. The Finnish National Nocturia and Overactive Bladder (FINNO) study found that the majority of people report having at least moderate bother when they experience three or more nocturnal voids and that the degree of bother increases with the number of nightly voids³. Furthermore, this study demonstrated that nocturia is associated with impaired health-related quality of life (HRQoL) as measured by the generic 15D HRQoL instrument⁴. Unfortunately, many individuals do not seek medical consultation for nocturia because of the perception that it is a normal part of aging or even that it is untreatable⁵.

This article aims to review the prevalence of nocturia along with its clinical consequences. A classification scheme for nocturia is presented and corresponding management strategies for each category are discussed.

Epidemiology

Prevalence rates for nocturia vary by age and gender, but all populations can be affected (Table 1)⁶. For both genders, there is a tendency for nocturia to increase with age. Nevertheless, it is important to identify and treat younger individuals with nocturia, since the detrimental effects of sleep fragmentation are especially difficult for those with active lifestyles and demanding work schedules⁶. A study in Finland reported higher rates of nocturia in women as compared to men for younger populations, but this gender difference disappeared at ages 50–59 and the prevalence became higher among men beyond the age of 60⁷.

Consequences of nocturia

By definition, nocturia results in sleep interruption, and thus it is axiomatic that this condition is associated with lower sleep quality. A multivariate analysis of elderly individuals (55–84 years of age) interviewed by the National Sleep Foundation showed that nocturia

was an independent predictor of self-reported insomnia and poor sleep quality⁸. In a cross-sectional analysis of the Sleep Heart Health study, patients with nocturia reported higher degrees of subjective sleepiness and had corresponding polysomnographic changes that indicated objectively worse sleep quality⁹. The first nocturnal void in particular has the potential to lower sleep quality, since it may occur during the first few hours of sleep, interrupting the restorative slow-wave sleep that takes place during this time¹⁰.

Sleep interruption has numerous negative consequences for those with nocturia, including daytime fatigue, difficulty concentrating, mood alterations, and decreased workplace productivity¹¹. Falls and bone fractures have been reported to occur at higher rates among those with nocturia; these events may occur during the day because of fatigue caused by nocturia or during the night when individuals rise to void¹². Several studies have explored even more severe consequences of nocturia, and a meta-analysis of 28,366 patients found that nocturia was associated with a 28% excess mortality risk per year¹³.

Evaluation of nocturia

The evaluation of patients with nocturia begins with a detailed history that includes questions relevant to voiding behavior^{1,2}. Underlying medical conditions that may account for increased voiding at night should be considered, and routine urine tests (i.e. dipstick or urinalysis) can be performed. Patients should also complete a frequency volume chart (FVC) in which they record the time and volume of each void over at least a 24-hour period. The FVC is a key diagnostic tool because it allows clinicians to classify each individual case of nocturia into one of four basic categories: global polyuria, nocturnal polyuria, reduced bladder capacity, and mixed. An overview of parameters that can be derived from the FVC is shown in Table 2.

Global polyuria

Global polyuria occurs when urine is produced in excess of 40 mL/kg bodyweight during a 24-hour period¹. Such urine

Table 1. Prevalence of nocturia.

	Prevalence Rates	
Men	One or more void per night	Two or more voids per night
20–40 years	11–35.2%	2–16%
>70 years	68.9–93%	29–59.3%
Women		
20–40 years	20.4–43.9%	4.4–18%
>70 years	74.1–77.1%	28.3–61.5%

Table 2. Parameters derived from frequency volume chart.

Parameter	Definition
NUV	Total nocturnal urine volume, including the first morning void
NPi	NUV / 24-hour urine volume
MVV	Maximum single voided volume over a 24-hour period
Ni	NUV/MVV
PNV	Ni – 1
ANV	Actual number of nocturnal voids
NBCi	ANV – PNV

MVV, maximum voided volume; NBCi, nocturnal bladder capacity index; Ni, nocturia index; NPi, nocturnal polyuria index; NUV, nocturnal urine volume; PNV, predicted number of nocturnal voids.

overproduction may simply be the result of increased fluid intake, or it may be the manifestation of an underlying disease, often stemming from the renal or endocrine system¹⁴. Examples of diseases causing global polyuria include poorly controlled diabetes mellitus, central or nephrogenic diabetes insipidus (DI), and primary polydipsia (psychogenic/behavioral or dipsogenic, latter due to brain trauma, radiation, or surgery with attendant dysfunctional thirst mechanism).

Nocturnal polyuria

Nocturnal polyuria occurs when urine is overproduced at night while 24-hour urine production volume remains normal. The proportion of urine produced at night can be quantified using the nocturnal polyuria index (NPi), which is calculated as the nocturnal urine volume (NUV) divided by 24-hour urine volume. Importantly, the NUV is defined as the total volume of urine voided during the night, including the first morning void. The ICS defines nocturnal polyuria in an age-dependent manner as nocturnal output greater than 20% of the daily total in the young and greater than 33% of the daily total in the elderly (NP33)¹.

By the NP33 definition, nocturnal polyuria may be present in up to 83% of those with nocturia⁷. Some have argued that this definition is too broad and lacking in clinical significance. In a meta-analysis of the difference in mean nocturnal voiding frequencies (NVFs) between patients with and without nocturnal polyuria, Hofmeester *et al.* found a mean difference in NVF of only 0.59¹⁵. Furthermore, a longitudinal, community-based study of 1,688 men aged 50–78 in Krimpen found that nocturnal polyuria was present in 70.1% of men without nocturia when the ICS definition was applied¹⁶.

These limitations have led to several alternative definitions for nocturnal polyuria. van Haarst *et al.* suggested still defining nocturnal polyuria based upon the NPi but raising the threshold to 53%, which corresponds to the 95% of NPi values¹⁷. Others have suggested definitions that move away from NPi entirely; in these cases, nocturnal polyuria may be defined as an NUV of >0.9 mL/minute, NUV of >6.4 mL/kg, or a nocturnal urine production rate of >90 mL/hour (NUP90)¹⁸. The NUP90 cutoff is based on the finding that the mean hourly urine production rate during sleep in the Krimpen study was 60 mL/hour and two standard deviations above that mean value was 90 mL/hour. An advantage of the NUP90 definition of nocturnal polyuria is that it can be calculated in patients who have supplied nocturnal-only diaries¹⁹.

As with global polyuria, nocturnal polyuria can be the result of specific behaviors (i.e. excessive nocturnal fluid intake) or the manifestation of underlying systemic disease. Obstructive sleep apnea (OSA) can lead to nocturnal polyuria owing to increased levels of circulating atrial natriuretic peptide (ANP), which promotes both water and osmotic diuresis. Peripheral edema for any reason—hepatic failure, nephrotic syndrome, or chronic venous insufficiency—can lead to nocturnal polyuria via third space fluid sequestration¹¹. This occurs when there is a net transfer of fluid from the extracellular (“third space”) compartment back into the intravascular compartment at night, which can provide an additional free water load that is removed by the kidneys. Those suffering from congestive heart failure (CHF) may experience nocturnal

polyuria via a combination of these mechanisms, as they may have elevated levels of ANP and fluid sequestered in the third space.

Reduced bladder capacity

Reduced bladder capacity occurs when there is discordance between urine production and the bladder’s ability to store urine, which can be global or nocturnal in nature. Reductions in nocturnal bladder capacity can be diagnosed through the nocturnal bladder capacity index (NBCi), where NBCi values above zero indicate that nocturia is occurring at voided volumes less than the MVV.

The pathophysiology of nocturia in patients with overactive bladder (OAB) or benign prostatic hyperplasia (BPH) may be the result of a reduced bladder capacity. In patients with OAB, detrusor overactivity can trigger the urge to void at volumes below the actual bladder capacity²⁰. A small but important study of nine patients with OAB and evidence of detrusor overactivity on cystometrograms found that these patients had a significantly greater mean number of nocturnal detrusor overactivity events as compared to controls and individuals with insomnia²¹. This study was unique in demonstrating the relationship between detrusor contractions and transformation of the polysomnogram from the sleeping to the awake state.

BPH can reduce bladder capacity via a different mechanism, whereby patients are left with high post-void residual volumes owing to the inability to completely empty the bladder²². A component of detrusor overactivity can be present in these patients when there is concomitant bladder outlet obstruction. If obstruction is left untreated or treated only with medical therapy, this overactivity may actually persist for long periods of time²³.

There are numerous other conditions, both urologic and non-urologic, that can lead to reduced bladder capacity (Table 3)²⁴.

Mixed

For some patients, analysis of the FVC will reveal the etiology of their nocturia to be mixed. A retrospective study of 200 patients with nocturia found that 36% were classified as mixed on the basis of having both nocturnal polyuria and a reduced nocturnal bladder capacity²⁵.

Table 3. Causes of reduced bladder capacity.

Bladder calculi
Ureteral calculi
Neoplasms of bladder, prostate, or urethra
Anxiety disorders
Learned voiding dysfunction
Pharmacologic agents
Neurogenic bladder
Cystitis
Extrinsic compression

Management strategies

Behavioral modification techniques are appropriate first-line treatment for patients with nocturia, regardless of the etiology. These include modifying global and evening fluid intake, restricting the consumption of foods that promote diuresis, and improving patient understanding of the physiology of storing and voiding urine²⁶. Further interventions can be tailored to each patient based upon the pathophysiology of their nocturia.

Global polyuria

The treatment for global polyuria will vary depending upon the underlying reason for increased urine production. Uncontrolled diabetes mellitus must be properly managed with appropriate lifestyle changes and medical therapy. Central DI can be treated with desmopressin, a vasopressin analog that promotes water reabsorption in the kidneys²⁷. High-dose tablet and low-dose sublingual forms of desmopressin have been found to reduce the mean number of nocturnal voids, even in patients without DI²⁸. Those with primary polydipsia may require psychotherapy in order to reduce their fluid intake²².

Nocturnal polyuria

Initial treatments for nocturnal polyuria should be directed at identifying and addressing any relevant systemic disease, such as CHF or OSA. In a meta-analysis of five studies, patients with OSA and nocturia had reductions in the frequency of nocturia and night-time urine volume after treatment with continuous positive airway pressure (CPAP)²⁹. In patients taking diuretics, the administration of these medications 6 hours prior to bedtime can reduce night-time frequency and the percentage of night-time voided volume³⁰. When peripheral edema is a concern, simple evening leg elevation or compression stockings can redistribute third space fluid⁹. As mentioned above, desmopressin can reduce nocturia severity, but its major adverse effect is hyponatremia³¹. Accordingly, serum sodium testing is advisable prior to beginning desmopressin therapy, especially for those over the age of 65, since these individuals are most at risk of developing hyponatremia³². For the newly approved desmopressin acetate nasal spray, clinical trials reported serum sodium levels of 126–129 in 1.4% of cases at a dose of 0.75 µg and in 2.0% of cases at a dose of 1.5 µg³³.

Reduced bladder capacity

Alpha-blockers are a central treatment for BPH, and a number of studies have explored their efficacy at treating associated nocturia. The Medical Therapy of Prostatic Symptoms trial found that doxazosin alone reduced the number of nightly voids by 0.54, only slightly outperforming placebo, which caused a reduction of

0.35³⁴. This study also suggested that 5-alpha-reductase inhibitors offer only minimal improvement in nocturia, a finding that has been borne out in several other studies^{35,36}.

Nocturia may improve following surgical interventions in those who have appropriate indications for such treatments. A prospective randomized study of 66 men with BPH and nocturia showed that transurethral resection of the prostate (TURP) reduced the mean number of nightly voids by one at 1-year follow-up, outperforming tamsulosin by 0.34 awakenings per night³⁷. Antunes *et al.* showed that the benefits of TURP at improving nocturia are present even in cases where the amount of resected tissue is less than 30%³⁸. Despite these findings, a study of 104 men who underwent radical prostatectomy found improvements following surgery in all domains measured by the American Urological Association symptom index, except for nocturia³⁹.

OAB medications appear to have minimal effect at treating nocturia. A meta-analysis comparing the efficacy of various antimuscarinics for those with OAB and nocturia found trospium chloride to be most effective, yet this medication reduced the mean number of nocturia episodes by only 0.24 compared with placebo⁴⁰. A separate study found that mirabegron reduced the mean number of nocturnal voids by only 0.39 compared to placebo⁴¹. The clinical significance of OAB medications is therefore likely limited for treating nocturia.

Conclusion

Nocturia is a prevalent condition that severely impacts quality of life for many individuals. It is important to recognize nocturia as an entity in its own right, since it is often misunderstood and, at times, even left untreated³. Nocturia is multifactorial in nature, so no single treatment will prove effective for all patients. Instead, treatments should be tailored to individuals based upon the type of nocturia revealed from FVC analysis.

Competing interests

Noam D. Fine declares that he has no competing interests. Jeffrey P. Weiss declares that he is an advisor for Ferring, Pfizer, Elsevier, Astellas, Allergan, Vantia, and Symptelligence. Alan J. Wein declares that he is an advisor for Allergan, AltheRx, Astellas, Axonics, Medtronic, and Serenity.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

1. van Kerrebroeck P, Abrams P, Chaikin D, *et al.*: **The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society.** *Neurological Urology*. 2002; 21(2): 179–83.
[PubMed Abstract](#) | [Publisher Full Text](#)

2. Hashim H, Blanks M, *et al.*: **An International Continence Society Report on the Terminology for Nocturia and Nocturnal Lower Urinary Tract Function.** Manuscript in Preparation.

3. Tikkinen KA, Johnson TM 2nd, Tammela TL, *et al.*: **Nocturia frequency,**

- bother, and quality of life: how often is too often? A population-based study in Finland. *Eur Urol*. 2010; 57(3): 488–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
4. Sintonen H: **The 15D instrument of health-related quality of life: properties and applications.** *Ann Med*. 2001; 33(5): 328–36.
[PubMed Abstract](#) | [Publisher Full Text](#)
 5. Chen F, Dai YT, Liu CK, *et al.*: **Perception of nocturia and medical consulting behavior among community-dwelling women.** *Int Urogynecol J Pelvic Floor Dysfunct*. 2007; 18(4): 431–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 6. Bosch JL, Weiss JP: **The prevalence and causes of nocturia.** *J Urol*. 2013; 189(1 Suppl): S86–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
 7. Tikkinen KA, Tammela TL, Huhtala H, *et al.*: **Is nocturia equally common among men and women? A population based study in Finland.** *J Urol*. 2006; 175(2): 596–600.
[PubMed Abstract](#) | [Publisher Full Text](#)
 8. Bliwise DL, Foley DJ, Vitiello MV, *et al.*: **Nocturia and disturbed sleep in the elderly.** *Sleep Med*. 2009; 10(5): 540–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 9. **F** Parthasarathy S, Fitzgerald M, Goodwin JL, *et al.*: **Nocturia, sleep-disordered breathing, and cardiovascular morbidity in a community-based cohort.** *PLoS One*. 2012; 7(2): e30969.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 10. Stanley N: **The Underestimated Impact of Nocturia on Quality of Life.** *Eur Urol Suppl*. 2005; 4(7): 17–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 11. Kobelt G, Borgström F, Mattiasson A: **Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia.** *BJU Int*. 2003; 91(3): 190–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 12. **F** Nakagawa H, Niu K, Hozawa A, *et al.*: **Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study.** *J Urol*. 2010; 184(4): 1413–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 13. Pesonsen JS, Cartwright R, *et al.*: **The Impact of Nocturia on Mortality: A Systematic Review and Meta-analysis.** *NeuroUrol Urodynam*. 2014; 33(6): 783–4.
 14. Gulur DM, Mevcha AM, Drake MJ: **Nocturia as a manifestation of systemic disease.** *BJU Int*. 2011; 107(5): 702–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
 15. **F** Hofmeester I, Kollen BJ, Steffens MG, *et al.*: **The association between nocturia and nocturnal polyuria in clinical and epidemiological studies: a systematic review and meta-analyses.** *J Urol*. 2014; 191(4): 1028–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 16. **F** van Doorn B, Blanker MH, Kok ET, *et al.*: **Prevalence, incidence, and resolution of nocturnal polyuria in a longitudinal community-based study in older men: the Krimpen study.** *Eur Urol*. 2013; 63(3): 542–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 17. van Haarst EP, Bosch JL: **A cutoff value based on analysis of a reference population decreases overestimation of the prevalence of nocturnal polyuria.** *J Urol*. 2012; 188(4): 869–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
 18. Hofmeester I, Kollen BJ, Steffens MG, *et al.*: **Impact of the International Continence Society (ICS) report on the standardisation of terminology in nocturia on the quality of reports on nocturia and nocturnal polyuria: a systematic review.** *BJU Int*. 2015; 115(4): 520–36.
[PubMed Abstract](#) | [Publisher Full Text](#)
 19. Denys MA, Cherian J, Rahnama'i MS, *et al.*: **ICI-RS 2015-Is a better understanding of sleep the key in managing nocturia?** *NeuroUrol Urodyn*. 2016.
[PubMed Abstract](#) | [Publisher Full Text](#)
 20. Abrams P: **Describing bladder storage function: overactive bladder syndrome and detrusor overactivity.** *Urology*. 2003; 62(5 Suppl 2): 28–37; discussion 40–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
 21. **F** Krystal AD, Preud'homme XA, Amundsen CL, *et al.*: **Detrusor overactivity persisting at night and preceding nocturia in patients with overactive bladder syndrome: a nocturnal cystometrograph and polysomnogram study.** *J Urol*. 2010; 184(2): 623–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 22. Dani H, Esdaille A, Weiss JP: **Nocturia: aetiology and treatment in adults.** *Nat Rev Urol*. 2016; 13(10): 573–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
 23. de Nunzio C, Franco G, Rocchegiani A, *et al.*: **The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction.** *J Urol*. 2003; 169(2): 535–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 24. Weiss JP, Blaivas JG, Van Kerrebroeck PE, *et al.*: **Nocturia: Causes, Consequences and Clinical Approaches.** Springer, 2012.
[Publisher Full Text](#)
 25. Weiss JP, Blaivas JG, Stember DS, *et al.*: **Nocturia in adults: etiology and classification.** *NeuroUrol Urodyn*. 1998; 17(5): 467–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
 26. Cho SY, Lee SL, Kim IS, *et al.*: **Short-term effects of systematized behavioral modification program for nocturia: a prospective study.** *NeuroUrol Urodyn*. 2012; 31(1): 64–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 27. Hammer M, Vilhardt H: **Peroral treatment of diabetes insipidus with a polypeptide hormone analog, desmopressin.** *J Pharmacol Exp Ther*. 1985; 234(3): 754–60.
[PubMed Abstract](#)
 28. Friedman FM, Weiss JP: **Desmopressin in the treatment of nocturia: clinical evidence and experience.** *Ther Adv Urol*. 2013; 5(6): 310–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 29. **F** Wang T, Huang W, Zong H, *et al.*: **The Efficacy of Continuous Positive Airway Pressure Therapy on Nocturia in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis.** *Int Neurourol J*. 2015; 19(3): 178–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 30. Reynard JM, Cannon A, Yang Q, *et al.*: **A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo.** *Br J Urol*. 1998; 81(2): 215–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 31. **F** Ebell MH, Radke T, Gardner J: **A systematic review of the efficacy and safety of desmopressin for nocturia in adults.** *J Urol*. 2014; 192(3): 829–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 32. Marshall SD, Raskolnikov D, Blanker MH, *et al.*: **Nocturia: Current Levels of Evidence and Recommendations From the International Consultation on Male Lower Urinary Tract Symptoms.** *Urology*. 2015; 85(6): 1291–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 33. **SER120 Nasal Spray Advisory Committee Briefing Document.**
[Reference Source](#)
 34. Johnson TM 2nd, Burrows PK, Kusek JW, *et al.*: **The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia.** *J Urol*. 2007; 178(5): 2045–50; discussion 2050–1.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Johnson TM 2nd, Jones K, Williford WO, *et al.*: **Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial.** *J Urol*. 2003; 170(1): 145–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 36. **F** Oelke M, Roehrborn CG, D'Ancona C, *et al.*: **Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies.** *World J Urol*. 2014; 32(5): 1141–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 37. **F** Simaloforidis V, Papatosis AG, Chrisofos M, *et al.*: **Tamsulosin versus transurethral resection of the prostate: effect on nocturia as a result of benign prostatic hyperplasia.** *Int J Urol*. 2011; 18(3): 243–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 38. Antunes AA, Srougi M, Coelho RF, *et al.*: **Transurethral resection of the prostate for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: how much should be resected?** *Int Braz J Urol*. 2009; 35(6): 683–9; discussion 689–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Schwartz EJ, Lepor H: **Radical retropubic prostatectomy reduces symptom scores and improves quality of life in men with moderate and severe lower urinary tract symptoms.** *J Urol*. 1999; 161(4): 1185–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. **F** Buser N, Ivic S, Kessler TM, *et al.*: **Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses.** *Eur Urol*. 2012; 62(6): 1040–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 41. **F** Chapple CR, Amarengo G, López Aramburo MA, *et al.*: **A proof-of-concept study: mirabegron, a new therapy for overactive bladder.** *NeuroUrol Urodyn*. 2013; 32(8): 1116–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Jin Wook Kim**

Department of Urology, Chung-Ang University, Seoul, South Korea

Competing Interests: No competing interests were disclosed.

2. **Altaf Mangera**

Department of Urology Research, Sheffield Teaching Hospitals NHS Trust, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK

Competing Interests: No competing interests were disclosed.

3. **Osamu Yokoyama**

Department of Urology, University of Fukui, Fukui, Japan

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research